Search Results - "WILLIS, JEFFREY R."

Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States by Willis, Jeffrey R, Doan, Quan V, Gleeson, Michelle, Haskova, Zdenka, Ramulu, Pradeep, Morse, Lawrence, Cantrell, Ronald A

“…Among adults with diabetes in the United States, severe forms of diabetic retinopathy (DR) are significantly associated with a greater vision-related…”
Get more information

Visual Field Loss and Accelerometer-Measured Physical Activity in the United States by van Landingham, Suzanne W., AB, Willis, Jeffrey R., MD, PhD, Vitale, Susan, PhD, MHS, Ramulu, Pradeep Y., MD, PhD

“…Objective To determine whether visual field (VF) loss is associated with lower levels of accelerometer-defined walking or physical activity in a nationally…”
Get full text

The Prevalence of Myopic Choroidal Neovascularization in the United States by Willis, Jeffrey R., MD, PhD, Vitale, Susan, MHS, PhD, Morse, Lawrence, MD, PhD, Parke, David W., MD, Rich, William L., MD, Lum, Flora, MD, Cantrell, Ronald A., PhD

“…Purpose To determine the prevalence of high myopia (HM), progressive high (degenerative) myopia (PHM), and myopic choroidal neovascularization (mCNV) in the…”
Get full text

INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE) by Wijesingha, Naomi, Gibson, Kara, Willis, Jeffrey R, Sivaprasad, Sobha

Get full text

Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs by Arcadu, Filippo, Benmansour, Fethallah, Maunz, Andreas, Michon, John, Haskova, Zdenka, McClintock, Dana, Adamis, Anthony P, Willis, Jeffrey R, Prunotto, Marco

“…To develop deep learning (DL) models for the automatic detection of optical coherence tomography (OCT) measures of diabetic macular thickening (MT) from color…”
Get full text

Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration by Chakravarthy, Usha, Bailey, Clare C., Johnston, Robert L., McKibbin, Martin, Khan, Rehna S., Mahmood, Sajjad, Downey, Louise, Dhingra, Narendra, Brand, Christopher, Brittain, Christopher J., Willis, Jeffrey R., Rabhi, Sarah, Muthutantri, Anushini, Cantrell, Ronald A.

“…To understand levels of disease burden and progression in a real-world setting among patients from the United Kingdom with bilateral geographic atrophy (GA)…”
Get full text

Visual impairment, uncorrected refractive error, and accelerometer-defined physical activity in the United States by Willis, Jeffrey R, Jefferys, Joan L, Vitale, Susan, Ramulu, Pradeep Y

“…To examine how accelerometer-measured physical activity is affected by visual impairment (VI) and uncorrected refractive error (URE). Cross-sectional study…”
Get more information

326-OR: Faricimab for Diabetic Macular Edema: A Novel Anti–Angiopoietin-2/Anti–Vascular Endothelial Growth Factor Bispecific Antibody in Clinical Trials by SHETH, VEERAL, SAHNI, JAYASHREE, STOILOV, IVAYLO, WILLIS, JEFFREY R., WEIKERT, ROBERT

“…In the United States, diabetic retinopathy (DR) and diabetic macular edema (DME) are a leading cause of blindness among working-age adults. The introduction of…”
Get full text

Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis by Cantrell, Ronald A., Lum, Flora, Chia, Yifeng, Morse, Lawrence S., Rich, William L., Salman, Craig A., Willis, Jeffrey R.

Get full text

86-OR: Primary Results from Two Phase 3 Trials of Faricimab for Diabetic Macular Edema (DME): YOSEMITE and RHINE by HU, ALLEN, WILLIS, JEFFREY R., HASKOVA, ZDENKA, SILVERMAN, DAVID, IVES, JANE, BASU, KAREN, LIN, HUGH

“…The leading cause of vision loss in people with diabetic retinopathy (DR) is DME. Intravitreal anti-VEGF therapy is the standard of care for DME; however,…”
Get full text

Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results by Regillo, Carl, Berger, Brian, Brooks, Logan, Clark, W. Lloyd, Mittra, Robert, Wykoff, Charles C., Callaway, Natalia F., DeGraaf, Stephanie, Ding, Han Ting, Fung, Anne E., Gune, Shamika, Le Pogam, Sophie, Smith, Robert, Willis, Jeffrey R., Barteselli, Giulio

“…To report 2-year results from the Archway clinical trial of the Port Delivery System with ranibizumab (PDS) for treatment of neovascular age-related macular…”
Get full text

Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials by Tadayoni, Ramin, Paris, Liliana P, Danzig, Carl J, Abreu, Francis, Khanani, Arshad M, Brittain, Christopher, Lai, Timothy Y Y, Haskova, Zdenka, Sakamoto, Taiji, Kotecha, Aachal, Schlottmann, Patricio G, Liu, Ying, Seres, András, Retiere, Anne-Cecile, Willis, Jeffrey R, Yoon, Young Hee

“…To evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibitor, faricimab, compared…”
Get full text

Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration by Kågedal, Matts, Alskär, Oskar, Petersson, Klas, Hanze, Eva, Maia, Mauricio, Lu, Tong, Vakhavkar, Shweta, Quartino, Angelica, Willis, Jeffrey R, Jin, Jin Y, Maass, Katie F

“…The port delivery system with ranibizumab (PDS) is designed to continuously deliver ranibizumab to maintain therapeutic drug concentrations in the vitreous of…”
Get full text

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 by Khanani, Arshad M, Kotecha, Aachal, Chang, Andrew, Chen, Shih-Jen, Chen, Youxin, Guymer, Robyn, Heier, Jeffrey S, Holz, Frank G, Iida, Tomohiro, Ives, Jane A, Lim, Jennifer I, Lin, Hugh, Michels, Stephan, Quezada Ruiz, Carlos, Schmidt-Erfurth, Ursula, Silverman, David, Singh, Rishi, Swaminathan, Balakumar, Willis, Jeffrey R, Tadayoni, Ramin

“…To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A.PURPOSETo evaluate…”
Get full text

Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema by von Schulthess, Esther L, Maunz, Andreas, Chakravarthy, Usha, Holekamp, Nancy, Pauleikhoff, Daniel, Patel, Katie, Bachmeier, Isabel, Yu, Siqing, Cohen, Yaniv, Scherb, Mahnaz Parian, Jones, Ian L, Gibson, Kara, Willis, Jeffrey R, Glittenberg, Carl, Singh, Rishi P, Fauser, Sascha

“…In diabetic macular edema (DME), hyper-reflective foci (HRF) has been linked to disease severity and progression. Using an automated approach, we aimed to…”
Get full text

Visual impairment, uncorrected refractive error, and objectively measured balance in the United States by Willis, Jeffrey R, Vitale, Susan E, Agrawal, Yuri, Ramulu, Pradeep Y

“…Further research is crucial to better understand the reason for falls in individuals with visual impairment (VI) and to develop appropriate fall prevention…”
Get more information

The Prevalence of Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS(®) Data Registry and NHANES by Willis, Jeffrey R, Vitale, Susan, Morse, Lawrence, Parke, 2nd, David W, Rich, William L, Lum, Flora, Cantrell, Ronald A

“…To determine the prevalence of high myopia (HM), progressive high (degenerative) myopia (PHM), and myopic choroidal neovascularization (mCNV) in the United…”
Get full text

Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes by Agostini, Hansjürgen, Abreu, Francis, Baumal, Caroline R, Chang, Dolly S, G Csaky, Karl, Demetriades, Anna M, Kodjikian, Laurent, Lim, Jennifer I, Margaron, Philippe, Monés, Jordi M, Peto, Tunde, Ricci, Federico, Rüth, Matthias, Singh, Rishi P, Stoilov, Ivaylo, Swaminathan, Balakumar, Willis, Jeffrey R, Westenskow, Peter D

“…Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related…”
Get full text

Potential Confounders in an Investigation of the Vision-Related Functional Burden of Diabetic Retinopathy-Reply by Willis, Jeffrey R, Doan, Quan V, Cantrell, Ronald A

Get more information

Development of Deep Learning Models to Predict Best-Corrected Visual Acuity from Optical Coherence Tomography by Kawczynski, Michael G, Bengtsson, Thomas, Dai, Jian, Hopkins, J Jill, Gao, Simon S, Willis, Jeffrey R

“…To develop deep learning (DL) models to predict best-corrected visual acuity (BCVA) from optical coherence tomography (OCT) images from patients with…”
Get full text